司库奇尤单抗治疗儿童重度斑块状银屑病:52周III期随机对照试验结果
这项多中心、双盲III期研究纳入162例6至<18岁重度慢性斑块状银屑病患者,随机接受司库奇尤单抗低剂量或高剂量、依那西普或安慰剂治疗。结果显示,司库奇尤单抗两种剂量在第12周对PASI 75和IGA 0/1的疗效均显著优于安慰剂(P<0.0001),且疗效维持至第52周,安全性特征与成人III期研究一致。
要点
- 司库奇尤单抗低剂量和高剂量在第12周PASI 75应答率分别为80.0%和77.5%,均显著优于安慰剂的14.6%(P<0.0001)。
- 第52周时,司库奇尤单抗低剂量和高剂量的PASI 75应答率均为87.5%,高于依那西普的68.3%。
- 安全性特征与成人III期研究一致,未发现新的安全信号。
核心结论
- 司库奇尤单抗低剂量和高剂量在儿童重度慢性斑块状银屑病患者中均表现出高且持续的疗效至第52周,安全性良好。
研究设计与样本
- 多中心、双盲、随机对照III期研究(NCT02471144),共随机162例6至<18岁重度慢性斑块状银屑病患者。
- 患者按体重(<25 kg、25至<50 kg、≥50 kg)和年龄(6至<12岁、12至<18岁)分层随机,接受司库奇尤单抗低剂量(75/75/150 mg)、高剂量(75/150/300 mg)、依那西普0.8 mg/kg(最大50 mg)或安慰剂治疗。
主要发现
- 第12周,司库奇尤单抗低剂量和高剂量组PASI 75应答率分别为80.0%和77.5%,安慰剂组为14.6%(P<0.0001)。
- 第12周,司库奇尤单抗低剂量和高剂量组IGA mod 2011 0或1应答率分别为70%和60%,安慰剂组为4.9%(P<0.0001)。
- 第12周,司库奇尤单抗低剂量和高剂量组PASI 90应答率分别为72.5%和67.5%,安慰剂组为2.4%(P<0.0001)。
- 第52周,司库奇尤单抗低剂量和高剂量组PASI 75/90/100应答率分别为87.5%/75.0%/40.0%和87.5%/80.0%/47.5%,依那西普组为68.3%/51.2%/22.0%。
- 第52周,司库奇尤单抗低剂量和高剂量组IGA 0或1应答率分别为72.5%和75.0%,依那西普组为56.1%。
关键数值与推荐
- 司库奇尤单抗低剂量方案:体重<25 kg或25至<50 kg为75 mg,≥50 kg为150 mg;高剂量方案:体重<25 kg为75 mg,25至<50 kg为150 mg,≥50 kg为300 mg。
- 依那西普剂量为0.8 mg/kg,最大不超过50 mg。
- 主要终点为第12周PASI 75和IGA mod 2011 0或1应答率。
临床怎么用
- 对于6至<18岁重度慢性斑块状银屑病患者,司库奇尤单抗低剂量或高剂量均可考虑作为治疗选择,疗效优于安慰剂和依那西普。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Secukinumab has demonstrated sustained long-term efficacy with a favourable safety profile in various psoriatic disease manifestations in adults. OBJECTIVES: Here, the efficacy and safety of two secukinumab dosing regimens [low dose (LD) and high dose (HD)] in paediatric patients with severe chronic plaque psoriasis over one year are reported. METHODS: In this multicentre, double-blind study (NCT02471144), patients aged 6 to <18 years with severe chronic plaque psoriasis were stratified and randomized by weight (<25 kg, 25 to <50 kg, ≥50 kg) and age (6 to <12 years, 12 to <18 years) to receive low-dose (LD: 75/75/150 mg) or high-dose (HD: 75/150/300 mg) subcutaneous secukinumab or placebo or etanercept 0.8 mg/kg (up to a max of 50 mg). RESULTS: Overall, 162 patients were randomized to receive secukinumab LD (n = 40) or HD (n = 40), etanercept (n = 41) or placebo (n = 41). The co-primary objectives of the study were met with both secukinumab doses (LD and HD) showing superior efficacy compared to placebo (P < 0.0001) with respect to PASI 75 response (80.0%, 77.5% vs. 14.6%) and IGA mod 2011, 0 or 1 response (70%, 60% vs. 4.9%) at Week 12. Both secukinumab doses were superior to placebo (P < 0.0001) with respect to PASI 90 response at Week 12 (72.5%, 67.5% vs. 2.4%). The efficacy of both doses was sustained to Week 52 with secukinumab achieving higher responses vs. etanercept (PASI 75/90/100: LD, 87.5%/75.0%/40.0% and HD, 87.5%/80.0%/47.5.% vs. etanercept, 68.3%/51.2%/22.0% and IGA 0 or 1: LD, 72.5% and HD, 75.0% vs. etanercept, 56.1%). The safety profile of secukinumab was consistent with the adult Phase 3 studies, with no new safety signals identified. CONCLUSIONS: Both doses of secukinumab demonstrated high and sustained efficacy up to Week 52 with a favourable safety profile in paediatric patients with severe chronic plaque psoriasis.
引用
- Bodemer C, Kaszuba A, Kingo K, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial. J Eur Acad Dermatol Venereol. 2021. PMID: 33068444. doi:10.1111/jdv.17002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。